HTA
RMD icon

Haber Trilix Advisors’s ResMed RMD Stock Holding History

Haber Trilix Advisors’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q2 		$7.08M Buy
+156,800
New +$7.44M 0.88% 34

Other funds holding RMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CBOA
Commonwealth Bank of Australia Sydney, NSW, Australia $355M AUM
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
LCG
Luxor Capital Group New York $2.52B AUM 29.31% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
WBC
Westpac Banking Corp Sydney, Australia $1.62B AUM 39.13% 1-Year Est. Return

Haber Trilix Advisors's RMD Position: Q2 2013 in Review

Haber Trilix Advisors opened a new position in ResMed (RMD) in Q2 2013: 156,800 shares worth $7.08M. The stake represents 0.88% of the portfolio and ranks #34 among its holdings.

313 funds tracked by Wall St. Rank hold RMD as of Q2 2013.

  • Haber Trilix Advisors held 156,800 shares of ResMed worth $7.08M as of Q2 2013.
  • ResMed was a new Haber Trilix Advisors position in Q2 2013.
  • ResMed made up 0.88% of Haber Trilix Advisors's portfolio in Q2 2013, its #34 holding.
  • 313 funds tracked by Wall St. Rank held ResMed as of Q2 2013.

Based on Haber Trilix Advisors's 13F filing for Q2 2013, filed 14 Aug 2013.